Related Experiment Video
Updated: Jul 8, 2026
06:26
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
A new model for academics based drug discovery.
1Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair, 65 Landsdowne Street, Cambridge, MA 02139, USA. rstein@rics.bwh.harvard.edu
Current Alzheimer Research
|January 29, 2008
Summary
New drug discovery models are needed to address rare diseases neglected by pharmaceutical companies. This presentation outlines a novel approach for developing treatments for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- Drug discovery is a complex, expensive process traditionally dominated by the pharmaceutical industry.
- Industry focus on profitable markets often leaves rare and neurodegenerative diseases underserved.
- There is a societal need for innovative models to drive research in neglected disease areas.
Purpose of the Study:
- To present a novel model for facilitating drug discovery in neglected disease areas.
- To specifically address the development of treatments for neurodegenerative diseases.
Main Methods:
- The presentation will describe a specific model designed for drug discovery.
- This model aims to overcome the financial barriers faced by traditional pharmaceutical research.
Main Results:
- The model has been established to find treatments for neurodegenerative diseases.
- Details on the model's specific mechanisms and successes will be discussed.
Conclusions:
- The established model offers a viable alternative for pursuing treatments for neurodegenerative conditions.
- This approach encourages drug discovery in areas neglected by the pharmaceutical industry due to financial constraints.
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:18Pharmacodynamic Models: Emax Drug–Concentration Effect Model
The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...